STADA

Press Releases

Press Releases

STADA subsidiary NIDDApharm enters the German vaccine market

Bad Vilbel, 06/29/1999 - The 100% STADA subsidiary NIDDApharm GmbH, Bad Vilbel, will move into the German vaccine market on July 1, 1999. This was announced today by the Chairman of the Board of STADA Arzneimittel AG, Hartmut Retzlaff, during this year’s General Meeting: This entry into the vaccine market comes about as part of STADA’s declared strategy, whereby it will continue to develop into a wide-ranging supplier in the health sector and at the same time expand into new and attractive market segments.

The vaccine market in Germany has a turnover of approximately DM 800 million at manufacturers’ sale prices and saw growth of approx. 6% in 1998. The vaccines of NIDDApharm will be actively promoted to doctors as from July 1,1999 by the 40 strong sales team.

NIDDApharm has selected highly qualified partners for its market launch. In Germany, NIDDApharm will market the vaccines of the renowned Swiss Serum and Vaccine Institute in Bern (Berna); and there is also a distribution partnership with the German state owned Robert Koch Institute.

The launch takes place on 01.07.1999 with the flu vaccine Inflexal S from Berna. NIDDApharm has high expectations of its sales in pharmacies, as STADA Group's high level of marketing skill in relation to this distribution channel is well known.

In addition, the launch product portfolio of NIDDApharm vaccines also includes Vivotif, an oral typhoid vaccine from Berna, and a live vaccine against yellow fever from the Robert Koch Institute. NIDDApharm expects to receive its German licence to distribute Berna's cholera vaccine in the Autumn.

A hepatitis A vaccine, with the brand name Epaxal, will follow shortly after as an additional NIDDApharm vaccine. Epaxal is the first vaccine patented with a new, so-called virosome technique. This innovative production technology produces a vaccine which gives rise to fast protection in the body whilst reducing the amount of the substance, and is particularly advantageous for the person receiving the vaccine. Through its extensive collaboration with Berna, NIDDApharm has secured the right to market future vaccines, employing this innovative design, in Germany.

To strengthen its competence in the vaccine market, NIDDApharm is supported by a scientific advisory committee, comprising of renowned vaccine experts from home and abroad, under the chairmanship of Dr. Schwarz, University of Würzburg. The work of the NIDDApharm vaccine advisory committee will focus in particular on the field of epidemiology and will be developing programmes for NIDDApharm aimed at a further improvement of the vaccination rate.

With its entry into the vaccine market, NIDDApharm, founded in August 1998, has taken an important step towards the further development of the company within the STADA Group.

Further information may be obtained from NIDDApharm under the telephone number

06101 - 603 990 or under the free fax number 06101 - 603 180.

For more information, please contact:

STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49 6101 603-113
Fax: +49 6101 603-506
e-mail: communications@stada.de

Career at STADA

Career at STADA

STADA's employees, with their extensive expertise, their experience and their strong commitment, play an important part in the longstanding success of the Group.

Learn more

Investor Relations

Investor Relations

Here you can find all the facts and background information about the STADA securities.

Learn more

Sustainability

Sustainability

For STADA "All the best" means taking responsibility.

Learn more

entdecken